Recent Updates
Recently added Catalysts
VRTX Neutral Sentiment

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Key Takeaway: Vertex Pharmaceuticals is set to announce its financial results for the first quarter of 2026 on May 4th. This announcement is a routine part of the company's financial reporting schedule. Investors and stakeholders will be looking for insights into the company's performance during this period.
Price reaction · baseline $438.71 (2026-04-02 close) · 1 other VRTX headline(s) in the window, move may be shared
day 0 close · peak
-1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
2.3%
average across 11 past catalysts
Lead asset
VX-880
Phase 3 · Diabetes Mellitus, Type 1

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2026 Earnings Call.”
The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website atwww.vrtx.comin the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America, and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit atwww.vrtx.comor follow us on LinkedIn, Facebook, Instagram, YouTube and X.
(VRTX-WEB)
Last updated: Apr 6, 2026